Clinical Trials Logo

Clinical Trial Summary

This is an immunogenicity and safety study of Gardasil (V501) in females 9 to 23 years of age in Korea.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT00157950
Study type Interventional
Source Merck Sharp & Dohme Corp.
Contact
Status Completed
Phase Phase 3
Start date October 2005
Completion date June 2006

See also
  Status Clinical Trial Phase
Completed NCT00973856 - Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands N/A
Active, not recruiting NCT05580341 - Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 Phase 3
Recruiting NCT03548740 - Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection
Completed NCT00092547 - A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Phase 3
Recruiting NCT00365729 - Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) - Types in HIV-positive Men N/A
Completed NCT03584308 - Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal Phase 2
Not yet recruiting NCT04115787 - Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN
Completed NCT04072913 - Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix N/A
Completed NCT00549250 - Human Papillomavirus 6/11 in the Lower Airway of Neonates N/A
Recruiting NCT04694495 - HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study
Completed NCT00380367 - Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029) Phase 3
Completed NCT01894425 - Human Papillomavirus and Rate of Pregnancy Achieved Via Medically Assisted Procreation N/A
Completed NCT00685412 - Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3 Phase 1
Completed NCT00365716 - Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED) Phase 2
Active, not recruiting NCT04772534 - Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066) Phase 3
Completed NCT05119855 - Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076) Phase 3
Completed NCT03487549 - Cantharidin and Occlusion in Verruca Epithelium Phase 2
Completed NCT02631863 - Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1) Phase 2
Completed NCT01245764 - GARDASILâ„¢ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) Phase 3
Completed NCT00461877 - High-Risk HPV Infections in Women Aged 25 to 65 N/A